This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Keedy, V. Articles by Carbone, D. P. Search for Related Content PubMed PubMed Citation Articles by Keedy, V. Articles by Carbone, D. P. Social Bookmarking                            What's this?

Phase I Study of Adenovirus p53 Administered by Bronchoalveolar Lavage in Patients With Bronchioloalveolar Cell Lung Carcinoma: ECOG 6597

Vicki Keedy, Wei Wang, Joan Schiller, Sunil Chada, Bonnie Slovis, Keith Coffee, John Worrell, Lyn A. Thet, David H. Johnson, David P. Carbone

From the Vanderbilt-Ingram Cancer Center, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Introgen Therapeutics Inc, Houston, TX; and The University of Wisconsin Cancer Center, Madison, WI

Corresponding author: David P. Carbone, MD, PhD, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Department of Medicine, 2220 Pierce Ave, 685 Preston Research Bldg, Nashville, TN 37232; e-mail: david.carbone{at}vanderbilt.edu

Purpose This pilot phase I trial evaluated the safety and maximum-tolerated dose of p53 gene transfer using an adenovirus vector (Ad-p53) delivered via bronchoalveolar lavage (BAL) to patients with bronchioloalveolar lung carcinoma (BAC).

Patients and Methods Patients were initially administered two treatments of Ad-p53 to a single involved lobe, beginning at 2 x 10⁹ viral particles (vp) per dose and escalated to a maximum of 2 x 10¹² vp. If a clinical benefit was seen and the treatment was well tolerated, additional doses could be administered to additional lobes.

Results Twenty-five patients were treated at doses between 2 x 10⁹ and 2 x 10¹² vp. At 2 x 10¹² vp, one patient experienced grade 4 pulmonary toxicity, and one patient died 25 days after his second cycle; therefore, a cohort of 10 patients was treated at the recommended phase II dose of 5 x 10¹¹ vp, with no grade 4 toxicity observed. The most frequent toxicities included low-grade fever, hypoxia, and dyspnea. Of the 23 assessable patients, 16 had stable disease as their best response. Subjective improvement in breathing was noted in eight patients. Limited distribution of vector was observed, with transient detection in patient sputum for 1 to 2 days after administration.

Conclusion Ad-p53 can be administered safely by BAL at 5 x 10¹¹ vp with repeated dosing. Stabilization of disease and symptomatic improvement may warrant further studies of Ad-p53 or other adenoviruses administered by BAL in patients with BAC.

Supported in part by Public Health Service Grants No. CA23318, CA66636, CA21115, CA49957, and CA21076; National Cancer Institute Specialized Program of Research Excellence in Lung Cancer Grant No. CA90949; and Cancer Center Core Grant No. CA68485 from the National Cancer Institute, National Institutes of Health, and the Department of Health and Human Services.

Presented in part at the 36th Annual Meeting of the American Society of Clinical Oncology, May 20-23, 2000, New Orleans, LA, and the 39th Annual Meeting of the American Society of Clinical Oncology, May 31-June 3, 2003, Chicago, IL.

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical Trials repository link available on www.JCO.org.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?